LAUSR

The management of duodenal neuroendocrine tumours (NET) between 1 and 2 cm is not codified. Currently, depending on the centre, endoscopic (ER) or surgical (SR) resection is offered. The main objective of our study was to describe the management of non-metastatic duodenal NETs in France. A study was conducted on 153 patients with non-metastatic duodenal NET diagnosed between 2000 and 2019 in 14 French centres by the GTE group (Endocrine Tumors Group). 58 (37.9%) patients treated with ER and 95 (62.1%) patients treated with SR were found. Surgery allowed significantly more complete resection than endoscopy (p < 0.001). ER margins were significantly less well-defined than SR margins (p < 0.001). Among the 51 patients with positive lymph node dissection, tumour size was ≤ 1 cm in 25 cases, between 1 and 2 cm in 14 cases and ≥ 2 cm in 12 patients. No difference in survival was demonstrated regardless of type of treatment. Surgical complications were more numerous than endoscopic complications (p = 0.001). Regardless of the type of incomplete resection, there was no significant difference between the two groups according to the criteria of location, size, grade, or adenopathy. In the subgroup analysis of duodenal NETs between 11 and 19 mm, the tumour stages were equivalent in pre-procedure between the two groups. In contrast, there was a difference in post-procedure after anatomopathological analysis (p = 0.001). Based on the study results, the type of endoscopic or surgical resection of duodenal NETs has no impact on the long-term results. Lymph node invasion is independent of tumour size.